Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Corporate Venture Seeds The Ecosystem To Grow Future Partners

This article was originally published in The Pink Sheet Daily

Executive Summary

Big pharma's venture arms are stepping in to fund early-stage companies with an eye toward increased opportunities for everyone.

You may also be interested in...



Abbott Adds Epigenetics To Its Anticancer R&D Through EpiTherapeutics Deal

Abbott broadens its approach to new cancer therapies by linking up with the Danish company EpiTherapeutics on modifying epigenetic regulation.

Abbott Adds Epigenetics To Its Anticancer R&D Through EpiTherapeutics Deal

Abbott broadens its approach to new cancer therapies by linking up with the Danish company EpiTherapeutics on modifying epigenetic regulation.

Corporate VC Funds Drive Innovation For Aileron’s Novel Stapled Peptide Technology

Aileron’s stapled peptides spark investment interest from four big pharma VC arms.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS068719

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel